The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation
© 2023 British Society for Haematology and John Wiley & Sons Ltd..
Allogeneic haematopoietic stem cell transplantation (HCT) is the curative treatment for myelodysplastic syndrome with a complex karyotype (CK-MDS). However, only a few studies have been limited to patients with CK-MDS undergoing allogeneic HCT. This study aimed to identify the risk factors for patients with CK-MDS undergoing allogeneic HCT. We included 691 patients with CK-MDS who received their first allogeneic HCT. The overall survival (OS) was the primary end-point, estimated using the Kaplan-Meier method. Prognostic factors were identified using a Cox proportional hazards model. The 3-year OS was 29.8% (95% confidence interval [CI]: 26.3-33.3). In the multivariable analysis, older age (hazard ratio [HR]: 1.44, 95% CI: 1.11-1.88), male sex (HR: 1.38, 95% CI: 1.11-1.71), poor haematopoietic cell transplant comorbidity index (HR: 1.47, 95% CI: 1.20-1.81), red blood cell transfusion requirement (HR: 1.58, 95% CI: 1.13-2.20), platelet transfusion requirement (HR: 1.85, 95% CI: 1.46-2.35), not-complete remission (HR: 1.55, 95% CI: 1.16-2.06), a high number of karyotype abnormality (HR: 1.63, 95% CI: 1.18-2.25) and monosomal karyotype (HR: 1.49, 95% CI: 1.05-2.12) were significantly associated with OS. Thus, the 3-year OS of allogeneic HCT was 29.8% in patients with CK-MDS, and we identified risk factors associated with poor OS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:204 |
|---|---|
| Enthalten in: |
British journal of haematology - 204(2024), 2 vom: 01. Feb., Seite 612-622 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shimomura, Yoshimitsu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allogeneic stem cell transplantation |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.19139 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363498206 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363498206 | ||
| 003 | DE-627 | ||
| 005 | 20240306232459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.19139 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM363498206 | ||
| 035 | |a (NLM)37857379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shimomura, Yoshimitsu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Allogeneic haematopoietic stem cell transplantation (HCT) is the curative treatment for myelodysplastic syndrome with a complex karyotype (CK-MDS). However, only a few studies have been limited to patients with CK-MDS undergoing allogeneic HCT. This study aimed to identify the risk factors for patients with CK-MDS undergoing allogeneic HCT. We included 691 patients with CK-MDS who received their first allogeneic HCT. The overall survival (OS) was the primary end-point, estimated using the Kaplan-Meier method. Prognostic factors were identified using a Cox proportional hazards model. The 3-year OS was 29.8% (95% confidence interval [CI]: 26.3-33.3). In the multivariable analysis, older age (hazard ratio [HR]: 1.44, 95% CI: 1.11-1.88), male sex (HR: 1.38, 95% CI: 1.11-1.71), poor haematopoietic cell transplant comorbidity index (HR: 1.47, 95% CI: 1.20-1.81), red blood cell transfusion requirement (HR: 1.58, 95% CI: 1.13-2.20), platelet transfusion requirement (HR: 1.85, 95% CI: 1.46-2.35), not-complete remission (HR: 1.55, 95% CI: 1.16-2.06), a high number of karyotype abnormality (HR: 1.63, 95% CI: 1.18-2.25) and monosomal karyotype (HR: 1.49, 95% CI: 1.05-2.12) were significantly associated with OS. Thus, the 3-year OS of allogeneic HCT was 29.8% in patients with CK-MDS, and we identified risk factors associated with poor OS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a allogeneic stem cell transplantation | |
| 650 | 4 | |a complex karyotype | |
| 650 | 4 | |a myelodysplastic syndrome | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Komukai, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Kitamura, Tetsuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Tachibana, Takayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kurosawa, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Itonaga, Hidehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tsukamoto, Shokichi |e verfasserin |4 aut | |
| 700 | 1 | |a Doki, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Ayumu |e verfasserin |4 aut | |
| 700 | 1 | |a Sawa, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ueda, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamae, Hirohisa |e verfasserin |4 aut | |
| 700 | 1 | |a Nawa, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Masatsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Yasuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Shuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kataoka, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nishida, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Junya |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Atsuta, Yoshiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ishiyama, Ken |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 204(2024), 2 vom: 01. Feb., Seite 612-622 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:204 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:612-622 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.19139 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 204 |j 2024 |e 2 |b 01 |c 02 |h 612-622 | ||